- ICH GCP
- Registro de ensaios clínicos dos EUA
- Ensaio Clínico NCT05593094
Um teste de fase 1 de cápsulas entéricas ZN-A-1041 ou combinação em pacientes com tumores sólidos avançados HER2-positivos
Um estudo clínico de fase 1 para avaliar a segurança, tolerabilidade, farmacocinética e eficácia das cápsulas entéricas ZN-A-1041 como agente único ou em combinação em pacientes com tumores sólidos avançados HER2-positivos
This will be a Phase 1, multicenter, open-label trial to evaluate the safety, tolerability, PK and efficacy of ZN-A-1041 as a monotherapy or in combination in participants with HER2-positive advanced solid tumors with or without brain metastases.
The study will consist of three phases: Phase 1a (dose escalation with ZN-A-1041 monotherapy), Phase 1b (dose escalation with ZN-A-1041 combination therapy) and Phase 1c (dose expansion with ZN-A-1041 combination therapy).
Visão geral do estudo
Status
Intervenção / Tratamento
- Medicamento: ZN-A-1041
- Medicamento: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1b
- Medicamento: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1b
- Medicamento: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1b
- Medicamento: ZN-A-1041 + T-DM1 3.6 mg/kg iv. for Phase 1c
- Medicamento: ZN-A-1041 + T-Dxd 5.4 mg/kg iv. for Phase 1c
- Medicamento: ZN-A-1041 + PHESGO / Herceptin plus Perjeta injection for Phase 1c
Descrição detalhada
This study is composed of three parts designed to evaluate the safety and efficacy of ZN-A-1041 in participants with HER2-positive advanced solid tumors.
Phase 1a (Monotherapy Dose Escalation): In this first phase, participants will receive ZN-A-1041 alone. The study will begin with a low dose of ZN-A-1041, which will be gradually increased in new groups of participants to find the highest dose that can be given safely. This will establish the recommended dose for further study.
Phase 1b (Combination Dose Escalation): In the second phase, the study will evaluate the safety of giving ZN-A-1041 together with established standard-of-care therapies for HER2-positive breast cancer. Participants will be enrolled into one of three combination arms to receive ZN-A-1041 with either T-DM1, T-DXd, or a pertuzumab/trastuzumab-based regimen. This phase will identify the recommended dose for these combination therapies.
Phase 1c (Combination Dose Expansion): In the final phase, additional participants will be enrolled to receive ZN-A-1041 at the recommended combination doses identified in Phase 1b. This will allow for a more thorough evaluation of the safety and preliminary efficacy of these treatment regimens.
Throughout the study, participants will undergo screening, treatment, and follow-up periods to collect comprehensive data on the safety, tolerability, pharmacokinetics, and anti-tumor activity of ZN-A-1041, both as a single agent and in combination.
Tipo de estudo
Inscrição (Estimado)
Estágio
- Fase 2
- Fase 1
Contactos e Locais
Locais de estudo
-
-
Victoria
-
Geelong, Victoria, Austrália, 3220
- Geelong Hospital
-
St Albans, Victoria, Austrália, 3021
- Sunshine Hospital
-
-
-
-
-
Barcelona, Espanha, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Espanha, 08028
- Instituto Oncologico Dr. Rosell-Hospital Universitari Dexeus-Grupo Quironsalud
-
Jaén, Espanha, 23007
- Hospital Universitario de Jaen
-
Madrid, Espanha, 28040
- Hospital Clinico San Carlos
-
Madrid, Espanha, 28041
- Hospital Universitario 12 de Octubre
-
Madrid, Espanha, 28007
- Hospital Beata Maria Ana
-
Seville, Espanha, 41009
- Hospital Universitario Virgen Macarena
-
Valencia, Espanha, 46010
- Hospital Clinico Universitario de Valencia
-
Valencia, Espanha, 46009
- Fundacion Instituto Valenciano de Oncologia (IVO)
-
-
Barcelona
-
Argentona, Barcelona, Espanha, 08310
- Instituto de Investigacion Oncologica Vall dHebron (VHIO) - EPON
-
-
LA Coruna
-
Santiago de Compostela, LA Coruna, Espanha, 15706
- Hospital Clinico Universitario de Santiago
-
-
Orense
-
A Gudiña, Orense, Espanha, 32540
- Hospital Universitario Ramon y Cajal
-
-
Sevilla
-
Las Cabezas de San Juan, Sevilla, Espanha, 41730
- Hospital Universitario Virgen del Rocio
-
-
-
-
Arizona
-
Tucson, Arizona, Estados Unidos, 85712
- Arizona Clinical Research Center, Inc.;Hematology Oncology Physicians - Aoa
-
-
California
-
Cerritos, California, Estados Unidos, 90703-2684
- TOI Clinical Research
-
San Francisco, California, Estados Unidos, 94158
- UCSF Helen Diller Family CCC
-
-
Massachusetts
-
Boston, Massachusetts, Estados Unidos, 02215
- Dana Farber Cancer Institute
-
-
Michigan
-
Ann Arbor, Michigan, Estados Unidos, 48109
- University of Michigan Hospital
-
Detroit, Michigan, Estados Unidos, 48201
- Barbara Ann Karmanos Cancer Institute
-
-
North Carolina
-
Durham, North Carolina, Estados Unidos, 27710
- Duke University School of Medicine
-
-
Texas
-
Houston, Texas, Estados Unidos, 77030-4000
- MD Anderson Cancer Center
-
-
-
-
-
Dijon, França, 21000
- Centre Georges Francois Leclerc
-
Lille, França, 59020
- Centre Oscar Lambret
-
Lyon, França, 69373
- Centre Léon Bérard Centre Régional de Lutte Contre Le Cancer Rhône Alpes
-
Marseille, França, 13009
- Institut Paoli-Calmettes
-
Saint-Herblain, França, 44805
- Institut de Cancerologie de l Ouest
-
Villejuif, França, 94800
- Gustave Roussy
-
-
Haute-Garonne
-
Toulouse, Haute-Garonne, França, 31059
- EDOG - Institut Claudius Regaud - PPDS
-
-
-
-
Emilia-Romagna
-
Parma, Emilia-Romagna, Itália, 43126
- Istituto Romagnolo per lo Studio dei Tumori Dino Amadori - IRST S.r.l - PPDS
-
-
Lombardy
-
Bergamo, Lombardy, Itália, 24127
- Asst Papa Giovanni XXIII
-
Magnago, Lombardy, Itália, 20020
- Fondazione Policlinico Universitario A Gemelli-Rome
-
-
-
-
-
Auckland, Nova Zelândia, 1023
- Auckland City Hospital
-
-
-
-
Lancashire
-
Manchester, Lancashire, Reino Unido, M20 4BX
- The Christie
-
-
Merseyside
-
Liverpool, Merseyside, Reino Unido, L69 3GL
- Clatterbridge Cancer Centre
-
-
Critérios de participação
Critérios de elegibilidade
Idades elegíveis para estudo
Aceita Voluntários Saudáveis
Gêneros Elegíveis para o Estudo
Descrição
Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
- Life expectancy of at least 6 months, as determined by the investigator
- Histologically or cytologically confirmed with unresectable or metastatic HER2-positive advanced solid tumors
- Must be relapsed or refractory after prior treatment for metastatic disease that included a taxane and trastuzumab or must have received first-line induction therapy for advanced disease a pertuzumab plus trastuzumab-based regimen or a T-DXd-based regimen
- Participants with new, untreated, progressive, or stable brain metastases are eligible
Exclusion Criteria:
- Participation in any other clinical study involving an investigational drug or device within 4 weeks prior to the first dose of study treatment
- Any intracranial lesion (brain metastasis) that requires immediate local therapy, such as surgery or radiation, or systemic corticosteroids at the time of enrollment
Plano de estudo
Como o estudo é projetado?
Detalhes do projeto
- Finalidade Principal: Tratamento
- Alocação: Não randomizado
- Modelo Intervencional: Atribuição sequencial
- Mascaramento: Nenhum (rótulo aberto)
Armas e Intervenções
Grupo de Participantes / Braço |
Intervenção / Tratamento |
|---|---|
|
Experimental: 1a: ZN-A-1041
Phase 1a: Participants will receive escalating doses of ZN-A-1041 orally twice a day (BID) at pre-defined dosing regimens to determine the maximum tolerated dose (MTD). |
ZN-A-1041: escalating doses orally BID at pre-defined dosing regimens to determine the MTD
Outros nomes:
|
|
Experimental: 1b: ZN-A-1041 + T-DM1 3.6 mg/kg iv.
Phase 1b Arm1:
|
ZN-A-1041: BID via oral administration T-DM1: 3.6 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Outros nomes:
|
|
Experimental: 1b: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.
Phase 1b Arm2:
|
ZN-A-1041: BID via oral administration T-DXd: 5.4 mg/kg given as an intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Outros nomes:
|
|
Experimental: 1b: ZN-A-1041 + PHESGO / Herceptin plus Perjeta
Phase 1b Arm3:
|
ZN-A-1041: BID via oral administration PHESGO dose is 600 mg pertuzumab/600 mg trastuzumab/2000 unites hyaluronidase every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta is 420 mg administered as an intravenous infusion Herceptin is 6 mg/kg administered as an intravenous infusion
Outros nomes:
|
|
Experimental: 1c: ZN-A-1041 + T-DM1 3.6 mg/kg iv.
Phase 1c Arm1: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b. |
ZN-A-1041: BID via oral administration T-DM1: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Outros nomes:
|
|
Experimental: 1c: ZN-A-1041 + T-Dxd 5.4 mg/kg iv.
Phase 1c Arm2: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b. |
ZN-A-1041: BID via oral administration T-DXd: intravenous infusion on the first day of each treatment cycle, once every 3 weeks (21-day cycle)
Outros nomes:
|
|
Experimental: 1c: ZN-A-1041 + Herceptin plus Perjeta/PHESGO
Phase 1c Arm3: The recommended dose combination for Phase 1c will be determined by the Investigator and the Sponsor based on the data from Phase 1b. |
ZN-A-1041: BID via oral administration PHESGO: every 3 weeks for subcutaneous administrations (21-day cycle) Perjeta: intravenous infusion Herceptin: intravenous infusion
Outros nomes:
|
O que o estudo está medindo?
Medidas de resultados primários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 as a Monotherapy in Phase 1a
Prazo: 23 days
|
Dose at which no more than one out of six participant at the same dose level experiences a probable drug-related DLT. |
23 days
|
|
The Incidence of Treatment-emergent Adverse Events of ZN-A-1041 in Combination with T-DM1 or with T-DXd, or in Combination with PHESGO or Herceptin plus Perjeta
Prazo: 21 days
|
Dose at which no more than one out of six participant at the same dose level experiences a probable drug-related DLT. |
21 days
|
|
RP2D
Prazo: Through study completion, an average of 1 year
|
To evaluate the safety of ZN-A-1041 in combination with T-DM1 or with T-DXd, or in combination with PHESGO or Herceptin plus Perjeta in participants on the RP2D. |
Through study completion, an average of 1 year
|
Medidas de resultados secundários
Medida de resultado |
Descrição da medida |
Prazo |
|---|---|---|
|
Plasma, Urine and Potentially Cerebrospinal Fluid (CSF) Level of ZN-A-1041 and its Main Metabolites
Prazo: From baseline to cycle 9 (each cycel is 21 days)
|
To assess the PK of ZN-A-1041 and its major metabolites. |
From baseline to cycle 9 (each cycel is 21 days)
|
|
Serum Level of Combination Drugs in Phase 1c
Prazo: Through study completion, an average of 2 year
|
To assess the serum concentration of combination drugs. |
Through study completion, an average of 2 year
|
|
Anti-drug Antibodies (ADAs) Evaluation in Phase 1c
Prazo: Through study completion, an average of 2 year
|
To assess the incidence of ADAs. |
Through study completion, an average of 2 year
|
|
Overall Response Rate (ORR)
Prazo: Through study completion, an average of 2 year
|
The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a, Phase 1b and 1c. |
Through study completion, an average of 2 year
|
|
Progression Free Survival (PFS)
Prazo: Through study completion, an average of 2 year
|
The preliminary efficacy of ZN-A-1041 as a monotherapy or combination in Phase 1a, Phase 1b and 1c. |
Through study completion, an average of 2 year
|
Colaboradores e Investigadores
Patrocinador
Investigadores
- Diretor de estudo: Clinical Trials, Hoffmann-La Roche
Datas de registro do estudo
Datas Principais do Estudo
Início do estudo (Real)
Conclusão Primária (Estimado)
Conclusão do estudo (Estimado)
Datas de inscrição no estudo
Enviado pela primeira vez
Enviado pela primeira vez que atendeu aos critérios de CQ
Primeira postagem (Real)
Atualizações de registro de estudo
Última Atualização Postada (Real)
Última atualização enviada que atendeu aos critérios de controle de qualidade
Última verificação
Mais Informações
Termos relacionados a este estudo
Palavras-chave
Termos MeSH relevantes adicionais
- Doenças Cerebrais
- Doenças do Sistema Nervoso Central
- Doenças do Sistema Nervoso
- Neoplasias por local
- Neoplasias
- Neoplasias do Sistema Nervoso
- Neoplasias do Sistema Nervoso Central
- Neoplasias Cerebrais
- Aminoácidos, peptídeos e proteínas
- Proteínas
- Produtos químicos orgânicos
- Compostos policíclicos
- Anticorpos, monoclonais, humanizados
- Anticorpos, monoclonais
- Anticorpos
- Imunoglobulinas
- Imunoproteínas
- Proteínas sanguíneas
- Globulinas de soro
- Globulins
- Macrolídeos
- Lactonas
- Lactamas, macrocíclicas
- Compostos macrocíclicos
- Maytansine
- Trastuzumabe
- Ado-Trastuzumabe Emtansina
- Pertuzumab
Outros números de identificação do estudo
- XO45189
- ZN-A-1041-101-US (Outro identificador: Suzhou Zanrong Pharma Limited)
- 2023-508459-37-00 (Ctis)
Plano para dados de participantes individuais (IPD)
Planeja compartilhar dados de participantes individuais (IPD)?
Descrição do plano IPD
For eligible studies, qualified researchers may request access to individual patient level clinical data. See Roche's commitment to transparency of clinical study information here: https://go.roche.com/data_sharing
Informações sobre medicamentos e dispositivos, documentos de estudo
Estuda um medicamento regulamentado pela FDA dos EUA
Estuda um produto de dispositivo regulamentado pela FDA dos EUA
Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .